Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease
Table 7
A logistic regression model of the OR of the increased serum level of IL-23 in systemic lupus erythematosus patients.
Covariates
Serum IL-23 > 0.0 pg/mL
Serum IL-23 > 3.1 pg/mL
OR (95% CI)
#
OR (95% CI)
#
Atherosclerotic plaque in cfa
10.12 (1.20–85.14)
0.033
0.066
4.26 (1.16–15.66)
0.029
0.058
Atherosclerotic plaque in lower extremity arteries in general
1.26 (0.48–3.32)
0.640
1.000
2.84 (1.02–7.91)
0.046
0.092
Obesity
3.83 (1.19–12.29)
0.024
0.024
3.88 (1.30–11.58)
0.015
0.015
Lupus nephritis
3.18 (1.06–9.54)
0.039
0.039
1.61 (0.52–4.97)
0.406
0.406
Anti-phosphatidylethanolamine IgG
12.67 (1.49–108.06)
0.020
0.100
0.71 (0.13–3.82)
0.687
1.000
Anti-phosphatidylethanolamine IgG or IgM
4.61 (1.19–17.88)
0.027
0.135
1.01 (0.28–3.62)
0.983
1.000
Anti-SS-B/La IgG
11.80 (1.47–94.77)
0.020
0.020
5.21 (1.53–17.71)
0.008
0.008
Anti-cardiolipin IgG
2.26 (0.90–5.71)
0.084
0.420
1.66 (0.61–4.49)
0.322
1.000
Anti-prothrombin IgG
8.35 (0.98–71.09)
0.052
0.260
0.64 (0.12–3.40)
0.598
1.000
IL-23: interleukin-23; cfa: common femoral arteries; OR: odds ratio; 95% CI: 95% confidence interval; #: after Bonferroni correction. OR and adjusted for sex and age.
